The Patent Finder
BR

BioNTech Rna Pharmaceuticals GmbH

First filing 2012
OverviewNotableFeesChangesFamiliesPatent listSources & methods

8 patents currently held

44 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Nov 2033. from the record

Of the 44 now held by other companies, 38 name BioNTech SE as their current owner, and 6 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2033
Next term end
6
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 205 later US patents, top 1% of utility patents granted in 2020 in our data. Protection runs to 2032.
now held by BioNTech SE
Ends May 2032 · High confidence
Also notable
Cited by 21 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2036.
now held by BioNTech SE
Ends Apr 2036 · High confidence
Also notable
Cited by 23 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2032.
now held by BioNTech SE
Ends Mar 2032 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 8 of 8

PatentTitleStatusExpiresConfidence
US 12,642,844Individualized Vaccines for Cancer
In force
 · High confidence
In forceHigh confidence
US 9,861,688T Cell Receptors with MHC Independent Binding to Gm-Csf Receptor Alpha Chain
In force
 · High confidence
In forceHigh confidence
US 10,987,413Novel MHC-Independent Tumor-Associated Antigens
In force
 · High confidence
In forceHigh confidence
US 12,220,484Stable Formulations of Lipids and Liposomes
held by BioNTech SE
In force
 · Low confidence
In forceLow confidence
US 12,168,051Methods and Compositions for Stimulating Immune Response
In force
 · High confidence
In forceHigh confidence
US 11,471,522Methods and Compositions for Stimulating Immune Response
In force
 · High confidence
In forceHigh confidence
US 12,281,1385'-CAP-TRINUCLEOTIDE- or Higher Oligonucleotide Compounds and Their Use in Stabilizing RNA, Expressing Proteins in Therapy
held by BioNTech SE
In force
 · High confidence
In forceHigh confidence
US 12,419,965RNA Particles Comprising Polysarcosine
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 8: 44 patents in force now held by others · 1 patent ended · 16 applications pending · 7 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited